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ABSTRACT
Glycosylation in cancer is a highly dynamic process that has a significant impact on 
tumor biology. Further, the attachment of aberrant glycan forms is already considered 
a hallmark of the disease state. Mass spectrometry has become a prominent approach 
to analyzing glycoconjugates. Specifically, matrix-assisted laser desorption/ionisation 
-mass spectrometric imaging (MALDI-MSI) is a powerful technique that combines 
mass spectrometry with histology and enables the spatially resolved and label-free 
detection of glycans. The most common approach to the analysis of glycans is the use 
of mass spectrometry adjunct to PNGase F digestion and other chemical reactions. 
In the current study, we perform the analysis of formalin-fixed, paraffin-embedded 
(FFPE) tissues for natively occurring bioactive glycan fragments without prior digestion 
or chemical reactions using MALDI-FT-ICR-MSI. We examined 106 primary resected 
gastric cancer patient tissues in a tissue microarray and correlated native-occurring 
fragments with clinical endpoints, therapeutic targets such as epidermal growth factor 
receptor (EGFR) and HER2/neu expressions and the proliferation marker MIB1. The 
detection of a glycosaminoglycan fragment in tumor stroma regions was determined to 
be an independent prognostic factor for gastric cancer patients. Native glycan fragments 
were significantly linked to the expression of EGFR, HER2/neu and MIB1. In conclusion, 
we are the first to report the in situ detection of native-occurring bioactive glycan 
fragments in FFPE tissues that influence patient outcomes. These findings highlight the 
significance of glycan fragments in gastric cancer tumor biology and patient outcome.
INTRODUCTION
Glycosylation is arguably the most abundant and 
complex type of protein posttranslational modification. In 
addition, alterations in the glycosylation of cancer cells are 
frequently a hallmark of disease states [1]. The attached 
modifications are glycans, which are assemblies of sugars 
(oligosaccharides and polysaccharides) that bind covalently 
to proteins or lipids (glycoconjugates), yielding protein/
lipid-glycan complexes that are separated into specific main 
families. N-linked glycans are added co-translationally in 
the endoplasmic reticulum at consensus Asn-X-Ser/Thr 
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motifs, whereas serine or threonine are glycosylated to form 
the O-linked family or glycosaminoglycans (attached to 
proteoglycans) [2]. The constitutions of glycans are complex 
and can be differentiated by sugar composition, branching 
structures, and molecular modifications (e.g. sulphation) 
among other properties [3]. Glycoconjugates are found 
almost everywhere in human tissue, including as nuclear or 
cytoplasmic proteins, as secreted product of epithelial cells 
(mucus), or as secreted molecules in the extracellular matrix 
[2]. The process of glycosylation is highly dynamic and 
involves biosynthesis and degradation, which can promote a 
fast response to cellular signals or cellular stages [4]. Specific 
interactions between glycoconjugates, cytokines, immune 
receptors, and enzymes have also been recognized [3]. In 
cancer tissues, altered glycosylation, such as incomplete 
synthesis and neo-synthesis processes, are highly associated 
with tumor biology [5]. A number of studies have reported an 
association between O-linked glycans and proliferation [2]. As 
well, molecular changes, including polysialic acid attachments 
of N-glycans, reportedly lead to poor outcome in lung cancer 
patients [6], whereas truncated glycan structures have been 
found to be prognostic markers in colorectal cancer [7].
It has also been shown in gastric cancer that 
glycosylation affects cell adhesion molecules, such 
as E-cadherin [8], and cell migration by the specific 
modification of integrin a3b1 [9]. The individual targeting 
therapy for gastric cancer patients is likewise influenced 
by glycosylation. In addition, prior in vitro studies have 
demonstrated that the expression levels and receptor 
activity of several receptor tyrosine kinases (RTK), such as 
HER2 and epidermal growth factor receptor (EGFR), were 
highly affected by N-linked glycosylation [10]. Further 
important influences on the modulation of the growth 
factors include the branching structure [11] and molecular 
modifications of the attached glycans [12]. Hence, due 
to the critical effects of glycosylation, there is a need to 
understand the underlying molecular mechanisms and to 
discover the clinical implications in gastric cancer.
Mass spectrometry is one method of choice for the 
reliable analysis of glycoconjugates in clinical samples 
[13-15]. However, the methods for studying glycans are 
hampered by a non-template driven biosynthesis (e.g. 
mRNA) and chemical heterogeneity [16]. The majority 
of former mass spectrometry analyses were based on 
digestion with the PNGase F enzyme, which is often used 
to release N-glycan structures from the protein core [17] 
and for reductive β-elimination of oxygen binding glycans 
[18]. Although the enzymatic and chemical changes 
increased measurability, they likewise hampered the 
ability to discriminate between the naturally occurring and 
formerly bound glycans. In fact, native-occurring glycan 
fragments are barely distinguishable in the abundant 
number of glycans present after release in vitro.
Matrix-assisted laser desorption/ionisation -mass 
spectrometry imaging (MALDI-MSI) is a powerful 
technique that combines mass spectrometry with 
histology, which enables the spatial resolution and label-
free detection of hundreds to thousands of compounds 
within a single tissue [19]. High mass resolution and 
accuracy, such as provided by Fourier transform ion 
cyclotron resonance (FT-ICR) mass spectrometry, enable 
the identification of compounds through exact mass 
matching. It has been established that cellular components, 
such as carbohydrates, are only trapped in the cross-links 
between proteins in formalin-fixed, paraffin-embedded 
(FFPE) tissues [20], which makes this class of molecules 
detectable by MALDI analysis. To this end, Powers et 
al. presented the first in situ n-glycan analysis using 
high mass resolution MALDI-MSI in combination with 
PNGase F digestion [17]. To the best of our knowledge, 
naturally occurring, unbound glycan structures have not 
yet been investigated in intact tissues.
In this study, we examined the native glycan 
structures in human FFPE tissues from gastric cancer 
patients without digestion or chemical reactions. The 
fundamental basis of investigating native glycan fragments 
is the possibility that FFPE tissues can be analysed by 
MALDI-FT-ICR-MSI as previously reported [21]. We 
also discovered that glycan structures could be measured 
following application of the MALDI-MSI protocol for 
FFPE tissue samples [21]. Herein, we present a first 
discovery approach to analysing native glycan fragments 
in situ by MALDI-FT-ICR mass spectrometry and to 
correlate their abundance with clinical endpoints and 
therapeutic targets such as EGFR and HER2/neu.
RESULTS
Mass spectrometry imaging reveals high 
variability of native glycans within and between 
patients
The MALDI-FT-ICR MSI analysis of a TMA, 
consisting of samples from 106 gastric cancer patients, 
resulted in the annotation of 17 native glycans amongst 
approximately 2000 m/z species over a mass range of 50–
800 m/z (Table 1). Distinct localization patterns of these 
glycan fragments were observed in whole tissue sections 
of individual patients (Figure 1) and between patients on 
the TMA (Figure 2) which illustrates the variability in 
abundance among the fragments. Examples of glycans 
with distinct distribution patterns are shown in Figure 2. 
A distinction between non-sulphated/sulphated and non-
acetylated/acetylated residues was, likewise, associated 
with differential distribution patterns (Figure 2). Looking 
at the histology of the tissues showed that each glycan 
could be assigned to a specific tissue compartment (e.g. 
tumor cells and/or tumor stroma, Figure 3A). Five glycans 
were present only in the tumor cell regions and four were 
only detected in the tumor stroma, whereas eight glycans 
were present simultaneously in both the tumor cell regions 
and the tumor stroma (Figure 3B). Based on available 
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databases and literature, the origins of four of the glycans 
detected were O-linked glycans, two were N-linked 
glycans, and 10 were glycosaminoglycan structures [2, 3].
Glycan validation experiments
Hydrolytic cleavage of hyaluronan and chondroitin 
sulphate yielded detectable HexS, HexNAcS, HexA–
HexNAc, HexA-HexNAcS and HexNAc-HexA-
HexNAc fragment signals. Based on a comparison of 
the fragmentation of the mentioned cleavage products 
and the tissue fragmentation patterns, two similar peaks 
were detected for HexS in the established mass range. 
By continuing validation process, two similar peaks were 
detected for HexP, two for HexNAcS, four for HexA-
HexNAc, three for HexA-HexNAcS and one for HexNAc-
HexA-HexNAc. The resulting validation spectra can be 
found in the Supplementary Material (Supplementary 
Figures 1 and 2). Additionally, all detectable glycan 
masses were crosschecked in the METLIN metabolite 
database and Human Metabolome Database (hmdb) for 
insure consisting annotations. No reasonable opposing 
annotation could be found.
Native glycans have a strong impact on patient 
outcomes
The survival analysis revealed significant relation-
ships between five glycans and patient prognosis (Figure 4). 
A high abundance of HexA (p = 0.0089), HexA–HexNAc 
(p = 0.0026), and HexNAc–HexA–HexNAc (p = 0.0132) 
in tumor cell regions resulted in a poor prognosis. 
Likewise, the increased abundance of Hex–HexAc (p = 
0.0375) and HexNAc–HexA–HexNAc (p = 0.0002) in 
tumor stroma regions was associated with poor patient 
prognosis. In contrast, a high abundance of HexS in the 
stroma regions was related to a positive patient prognosis 
(p = 0.0190). The calculation of the multivariate statistical 
analysis revealed that HexNAc–HexA–HexNAc [p = 
0.0064; hazard ratio (HR), 1.0215], especially in the tumor 
stroma regions, served as an independent prognostic factor 
(Table 2) against the established Union for International 
Cancer Control (UICC) classification.
Correlation of glycan fragments indicates 
naturally occurring degradation processes
Tumor cell regions and tumor stroma regions were 
calculated separately. Spearman’s correlation matrixes were 
constructed (Figure 5A and 5B) based on the intensities of 
native glycan fragments by MALDI-FT-ICR to investigate 
the internal correlations within glycan fragments. In the 
tumor cell regions (Figure 5A), 16 specific molecular 
correlations were observed. HexNAc–HexA–HexNAc 
was positively correlated with HexA (p ≤ 0.0001), HexA–
HexNAc (p = 0.0003), and HexA–HexNAcS (p ≤ 0.0001). 
Particularly these three molecules are directly linked by one 
Table 1: List of all native glycan fragments detected.
# Abbreviation m/z Localization
1 HexA 193.0350 Tumor/Stroma
2 PenSMe 243.0170 Tumor
3 HexS 259.0130 Tumor/Stroma
4 HexP 259.0220 Tumor/Stroma
5 HexNAcS 300.0400 Tumor/Stroma
6 HexA–HexN 354.1035 Stroma
7 dHex–PenS 375.0618 Tumor/Stroma
8 Hex–HexAc 383.1210 Tumor/Stroma
9 HexA–HexNAc 396.1145 Tumor
10 HexNAc–HexNAc 424.1473 Tumor/Stroma
11 Pen–Hex–dHex 457.1573 Tumor
12 Sia–Hex 470.1500 Tumor
13 HexA–HexNAcS 476.0715 Tumor
14 HexNAc–HexA–HexNAc 599.1960 Tumor/Stroma
15 HexAcAcAc–HexAcAcAc 635.1832 Stroma
16 HexAS–HexNAcSS 635.9866 Stroma
17 dHex–dHex–dHex–HexNAc 658.2565 Stroma
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degradation process [22, 23]. Conversely, HexA–HexNAc 
mass intensities were inversely correlated with HexP (p ≤ 
0.0001). HexNAc–HexA–HexNAc was likewise correlated 
with HexA (p ≤ 0.0001) in the tumor stroma regions 
(Figure 5B). In summary, three significant correlations were 
detected in the tumor stroma regions.
Incidence and prognostic relevance of HER2/
neu, EGFR and MIB1
IHC staining for HER2/neu, EGFR and the proliferation 
marker MIB1, was performed in adjacent TMA tissue 
sections. A HER2/neu IHC score of 3 was found in 9.6% of the 
Figure 1: Detectable native glycan fragments and whole gastric cancer tissue section ion map. (A) Detectable glycan 
fragments were in the mass range of 190–660 m/z and are shown as symbols with numbers. The explanation of the symbols used 
(according to GlycoWorkbench) can be found in the caption in the right bottom corner. The numbers refer to Table 1. (B-D) Ion map of 
N-acetylhexosamine sulphate, hexose sulphate, and hexuronic acid N-acetylhexosamine in whole tissue sections from a gastric cancer 
patient. Every tissue section corresponds to an individual patient and highlights altered specific distribution of each glycan fragment.
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Table 2: Stepwise Cox regression analysis and hazard ratios of overall survival with prognostic factors.
Multi-variate 
P-Value HR 95% Confidence Int.
Tumor cell regions
HexA 0.1010 1.0128 0.9975–1.0280
HexA–HexNAc 0.8220 0.9973 0.9745–1.0210
HexNAc–HexA–HexNAc 0.8260 1.0028 0.9784–1.0280
UICC-Stage 0.1280 1.3371 0.9201–1.9430
Tumor stroma regions
HexS 0.5135 0.9914 0.9661–1.0170
HexA–HexAc 0.2131 1.0085 0.9951–1.0220
HexNAc–HexA–HexNAc 0.0064 1.0215 1.0060–1.0370
UICC-Stage 0.1351 1.4278 0.8950–2.2780
Figure 2: Ion maps of different glycan fragments analyzed in the gastric cancer tissue microarray. The H&E figure 
serves a histological overview. Ion map distribution patterns of the native glycan fragments HexNAc-HexNAc, HexNAcS, HexA-HexAc, 
HexS and Sia-Hex are specific for patients and tissue compartments. The measured m/z values as well as the symbols (according to 
GlycoWorkbench) are displayed on the right side in each case.
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samples, whereas 37.7% of the samples exhibited low HER2/
neu expression (IHC Score of 1 or 2). However, the majority 
(52.7%) of the patients were HER2/neu negative. An EGFR 
IHC Score of 3 was found in 17.0% of the stained patient 
tissues, whereas 19.3% and 5.7% of the stained patient tissues 
had an EGFR IHC Score of 1 and 2, respectively. Similar to 
HER2/neu, most patient tissues (58.0%) were EGFR negative. 
MIB1 Score 3 was detected in 14.1% of the patients, and Score 
2 in 42.4% of the patient cohort. Overall, 30.6% of the patients 
showed MIB1 Score 1 and 12.9 % Score 0. All resulted score 
values are included in Table 3. The prognostic Kaplan-Meier 
calculations for HER2/neu and MIB1 were significant (p = 
0.0002, and p = 0.0481, respectively). However, EGFR did 
not correlate with patient survival.
Glycan fragment abundance is related to distant 
metastases (pM) and expression of HER/2neu, 
EGFR and MIB1
The glycan fragment abundances were tested for 
correlation with further available clinical data (Table 3). 
In order to do so, a Spearman’s correlation matrix was 
generated between MSI intensities of the detected 
glycans, the pTNM classification, and the therapeutic 
target expression status in the tumor cell regions, which 
resulted in 36 significant correlations (Figure 5C). The 
appearance of distant metastases (pM) was correlated 
with the abundance of methyl pentose sulphate (PenSMe; 
p = 0.0387) and Sia-Hex was positively correlated with 
EGFR (High intensities of Sia-Hex were followed by 
increased EGFR expression (p = 0.0363)). As well, 
increased detection of HexA–HexNAc was associated 
with low MIB1 (p = 0.0357) and HER2/neu (p = 0.0420) 
expression (Figure 5C). Ion map images of Sia-Hex and 
HexA–HexNAc further demonstrated the correlation 
between glycan mass abundance, EGFR, and HER2/neu 
expression (Figure 6). While Sia-Hex molecules were 
mainly localized in the mucus of tumor cells, HexA–
HexNAc was localized to the tumor cell regions and 
indicated decreased HER2/neu expression (Figure 6).
DISCUSSION
We present the first attempt at analyzing native 
glycan fragments in FFPE tissues by MALDI-FT-ICR-
MSI, the results of which offer novel insights into the 
composition and distribution of glycans in gastric cancer 
tissues. Our study shows that even without PNGase F 
digestion, it was possible to detect naturally occurring 
glycans. Furthermore, our approach enabled the detection 
of correlations between glycan degradation products, 
patient outcome, HER2/neu and EGFR expression, pM 
and MIB1.
In contrast to PNGase F digestion, our approach 
does not require additional washing steps after 
deparaffinisation [19, 21]. As well, the exclusion of polar 
solvents, such as ethanol, might enable the analysis of 
native water-soluble fragments and represents one of the 
major differences between former glycan studies and the 
current analysis. An interesting finding was the ability to 
differentiate the molecular modifications of glycans such 
as sulphatation and phosphatation. A condition that is 
Figure 3: Regions of interests (virtual microdissection) 
separating tumor cells and tumor stroma. (A) The 
gastric cancer tissue microarray was divided into specific cell 
compartments by defining the regions of interests in the tumor 
and tumor stroma areas. (B) Venn-diagram illustrating the 
distribution of glycan fragments in the regions of interests.
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Figure 4: Survival analysis of glycan fragments. Tumor cell regions and tumor stroma regions were considered individually. (A) 
Presence and abundance of glycan fragments detected only in tumor cell regions. The high abundance of HexA, HexA–HexNAc, and 
HexNAc–HexA–HexNAc in tumor cells resulted in poor prognosis. (B) With respect to the tumor stroma regions, increased intensities of 
Hex–HexAc and HexNAc–HexA–HexNAc corresponded to an unfavorable patient prognosis. In contrast, a high abundance of HexS in 
tumor stroma regions was associated with a positive patient prognosis. The relative intensity of small peaks (pictured) served as basis for 
the prognostic calculation.
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required for the detection of such subtle mass differences 
is the use of a high-resolution mass analyzer such as a FT-
ICR [19]. Using MALDI-FT-ICR, spatial differences in 
the distribution patterns of related degradation products, 
including HexA–HexNAc and HexNAcS, were detected, 
which furthered our understanding of the biological 
degradation and modification processes. The decreased 
abundance of sulphated glycan agents might lead to the 
assumption that the activity of sulphation enzymes has 
been lost. For example, in some tissue compartments, 
chondroitin 4-sulfotransferase could be involved in the 
specific distribution patterns, which indicates partial 
colocalization and separation of sulphated and non-
sulphated glycan fragments [24].
The survival analysis revealed a relationship between 
specific native glycan structures in tumor biology, which 
makes this class of enzymatic degradation products an 
interesting target for future prognostic studies of gastric 
and other cancer types. The abundance of HexNAc–
HexA–HexNAc has been revealed as an independent 
Figure 5: Correlation-Plots. (A, B) The glycan fragment intensities measured and the internal mass correlations. Plot (A) details the 
tumor cell regions and Plot (B) shows the tumor stroma regions. Plot (C) contains plot (A) in addition to the clinical and immunohistochemical 
staining results. The sizes of the squares are dependent on the Spearman’s rank correlation coefficient. Blue squares correspond to positive 
correlations and red squares correspond to negative correlations. Insignificant correlation results (p > 0.05) are indicated by an empty square.
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prognostic factor for gastric cancer patients. Remarkably, 
this independent prognostic factor is localized in the tumor 
stroma regions, which indicates the importance of the 
stroma to tumor biology as previously shown for pancreatic 
cancer [25]. Stroma-related genes in gastric cancer have 
already been associated with patient survival [26].
Former studies have revealed that glyco-
saminoglycan digestion fragments can act as regulators 
of primary tumor growth [27]. Likewise, in vitro 
experiments have demonstrated that glycosaminoglycans 
fragments significantly inhibited primary tumor growth 
by approximately 70% [27]. Following the injection of 
mice with glycan fragments generated by heparinase 
III, a 75% reduction in lung invasion was observed 
[27]. In the present study, a prognostic influence of 
bioactive glycosaminoglycan fragments could occur 
in patients because of these changing effects in tumor 
biology. In that light, it could be that all native glycan 
fragments with prognostic relevance are associated with 
glycosaminoglycans. Based on these results we conclude 
that these small bioactive digestion fragments have a 
significant effect on patient outcomes. To this end, glycan 
fragments could function as a messenger and might have 
an impact on metastatic behavior and tumor growth. 
Furthermore, the glycosaminoglycan fragment HexA–
HexNAc was significantly correlated with the expression 
of HER2/neu. Another explanation for the observed 
prognostic effects could be related to the resulting 
fragment intensities, which could be strongly correlated 
with the abundance of the previously existing high-
molecular weight glycoconjugates. Chondroitin sulphate, 
which is already recognized as a prognostic factor in 
ovarian cancer [28], could likewise explain the observed 
prognostic effects of the degradation products HexA, 
HexA–HexNAc, and HexNAc–HexA–HexNAc, because 
all of these products are associated with its degradation 
[22, 23]. With the usage of immunohistochemistry, a 
previously study found that the aberrant glycan structure 
sialosyl-Tn antigen is involved in the outcome of gastric 
cancer patients [29]. In contrast to this study, the detected 
bioactive glycan fragments in our study cannot be 
detected by immunohistochemistry instead of by mass 
spectrometry.
Another important result in this study was the 
detection of a correlation between the identified glycans 
and therapeutic targets. A highly regulated and critical 
step in the mutation of transmembrane RTK glycoproteins 
is N-linked glycosylation [12]. In previous studies, the 
expression levels and receptor activity of RTKs, such 
as EGFR and HER2, were highly affected by N-linked 
glycosylation [12], which is dependent on the sialyation 
and fucosylation level of the attached glycans [12]. Our 
findings suggest that Sia-Hex is a likely indicator of 
the sialyation level of N-glycans, followed by EGFR 
activation in tissues. An increased abundance of Sia-
Table 3: Patient characteristics.
Value
Number of patients [n] 106
Gender ratio [%] Male 62
Female 38
Age [years] Mean 69
Range 34–90
Survival time Median 303
[months] Range 4–737
Lauren classification Intestinal 41
ratio [%] Nonintestinal 59
pT [%] T1 0
T2 37.7
T3 50.9
T4 11.4
pN [%] N0 19.0
N1 26.7
N2 35.2
N3 19.1
pM [%] M0 71.6
M1 28.4
UICC-stage [%] Stage 1 11.5
Stage 2 16.7
Stage 3 25.6
Stage 4 46.2
G [%] G1 1.0
G2 16.0
G3 83.0
HER2/neu [%] Score 0 52.7
Score 1 23.7
Score 2 14.0
Score 3 9.6
EGFR [%] Score 0 58.0
Score 1 19.3
Score 2 5.7
Score 3 17.0
MIB1 [%] Score 0 12.9
Score 1 30.6
Score 2 42.4
Score 3 14.1
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Hex correlated with elevated EGFR expression levels 
in patient tissues. In contrast, the increased intensity of 
the glycosaminoglycan fragment HexA–HexNAc was 
correlated with low HER2/neu expression.
It could be assumed that the negative correlation 
of the glycosaminoglycan fragment HexA-HexNAc 
would probably be a result of previously existing high-
molecular weight hyaluronan. Former studies in breast 
cancer revealed that an accumulation of hyaluronan 
is associated with tumor progression and HER2/neu 
positivity [30]. Notably, the interaction of hyaluronan and 
CD44 receptors can modulate the activity of HER2 family 
members [30]. Accordingly, the degradation of hyaluronan 
by hyaluronidases hampers accumulation [31] and release 
hyaluronan fragments like HexA-HexNAc. The detection 
of the glycosaminoglycan fragment could be associated 
Figure 6: Simultaneous consideration of MALDI FT-ICR-MSI and results of the EGFR and HER2/neu 
immunohistochemical staining. The left cores in (A) show the Sia-Hex ion map of two individual patients. Sia-Hex was 
positively correlated with EGFR. High abundances of Sia-Hex were observed in accord with high EGFR expression, as indicated in the 
immunohistochemical staining with EGFR in the two right cores in (B). In contrast, (C) contains the HexA–HexNAc ion map, which was 
negatively correlated with HER2/neu expression. High HexA–HexNAc mass intensities were accompanied by low expression of HER2/
neu, which can be observed in (D).
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with a functional degradation process and therefore could 
indicate a lower HER2/neu expression.
The results of this study improve our understanding 
of gastric cancer tumor biology through the successful 
analysis of small bioactive glycans in human cancer 
tissues. Hence, the investigation of native glycan 
composition of other tumor types could enhance existing 
therapeutic and clinical implications for other cancers. 
Combining the analysis of native glycans with PNGase F 
digestion or β-elimination reactions could likewise be an 
interesting approach for further analysis. The interactions 
and specific distribution patterns of glycoconjugates and 
native fragments partly digested with PNGase F would 
be very interesting and would improve our understanding 
of the role of glycosylation in tumor biology. Previously 
published multimodal workflow for the simultaneous 
analysis of proteins and glycans [32] demonstrated the 
potential of MALDI-MSI; thus, expanding prior workflow 
to include the analysis of native glycans, especially those 
present in the mass range of 50–800 m/z, was considered 
plausible.
An interesting future prospect would be the analysis 
of glycan fragments in the blood. Based on the high 
abundance of glycans observed in tumor stroma regions 
and the apparent correlation with tumor biology, current 
findings indicate that glycan fragments could prove to be 
useful biomarkers in gastric cancer patients. Changing 
of glycosylation in cystic fluids is already showing a 
potential for ovarian tumor staging and classification [33].
In conclusion, our data demonstrates the first 
approach that native glycan fragments can be measured 
in FFPE tissues and are associated with tumor biology 
and related processes such as patient outcomes and 
the expression of HER2 and EGFR. These findings are 
highlighting the significance of native glycan fragments 
in gastric cancer patients.
MATERIALS AND METHODS
Collection of tissue samples and 
clinicopathological data
Primary surgical resection specimens were preserved 
from gastric adenocarcinoma patients (n = 106, Table 3). 
Samples were collected between 1995 and 2005 at the 
Department of Surgery, Klinikum Rechts der Isar, Munich, 
Germany. Data were acquired with approval from the ethics 
committee of the Technical University Munich. None of 
the patients had received pre- or perioperative neoadjuvant 
treatment. Follow-up data for the patients were assessable 
and survival rates could be calculated using the date of last 
follow-up or death. The mean age at surgery was 69 years 
and the median survival time was 303 months. The used 
tissue microarray (TMA) was constructed by sampling 
tumor tissue with a core size of 1 mm from each paraffin-
embedded tissue block. FFPE sections (3 μm) were 
mounted onto indium-tin-oxide (ITO)-coated glass slides 
(Bruker Daltonik GmbH, Bremen, Germany) pretreated 
with 1:1 poly-L-lysine (Sigma-Aldrich, Munich, Germany) 
and 0.1% Nonidet™ P-40 (Sigma-Aldrich).
MALDI-FT-ICR imaging mass spectrometry
The FFPE TMA sections were incubated for 1 
h at 70°C, deparaffinised in xylene (2 × 8 min), and 
allowed to air-dry. The detailed information regarding 
MALDI-MSI and matrix application can be found in the 
protocol by Ly & Buck et al. [19, 21]. Briefly, the FFPE 
samples were covered with 10 mg/ml 9-aminoacridine 
matrix in 70% methanol using a SunCollect sprayer 
(Sunchrom, Friedrichsdorf, Germany) [34] and analyzed 
in negative ion mode on a Bruker Solarix 7.0 T FT-
ICR MS (Bruker Daltonik) over a mass range of m/z 
50–800 and at a lateral resolution of 70 μm. Non-tissue 
regions were measured as a background control for 
differentiating between tissue and matrix-associated 
peaks. After the acquisition, the matrix was removed 
with 70% ethanol, the samples were stained with H&E, 
coverslipped, scanned with a Mirax Desk scanner 
(Zeiss, Göttingen, Germany) using a 20× magnification 
objective, and co-registered with the respective 
MSI data using flexImaging™ v. 4.0 (Bruker). The 
flexImaging™ software was used for normalization 
against the root mean square of all data points. Tissue 
cores were processed by “virtual microdissection” with 
the definitions of regions of interests to tumor cell and 
tumor stroma areas as previously described [35]. The 
specification of regions of interests and the exportation 
of each patient’s spectral data was likewise managed by 
flexImaging™ [34].
MALDI-FT-ICR MSI data processing
For subsequent data processing, a MATLAB script, 
including the bioinformatics and image processing 
toolboxes (v.7.10.0, MathWorks, Natick, MA, USA), was 
generated. In this script, the from flexImaging™ exported 
spectra were processed by the LIMPIC algorithm [36]. 
This includes a baseline subtraction (100 data points 
window size), resampling (m/z 0.001 bin width) and 
smoothing (Kaiser filter with factor 3) to remove chemical 
and electronic noise prior to peak picking. Peak picking 
was performed with parameters defining a minimal peak 
width of m/z 5.0E-4, a signal-to-noise threshold of 2, and 
a minimum intensity threshold of 0.01% with respect to 
each spectrum’s base peak. To enable direct comparability 
between peak lists from different patients, peaks were 
clustered with a certain mass tolerance (5.0E-8* m/z2.023). 
Only peaks found in more than four different patient 
tissues in each comparison group (tumor cells or tumor 
stroma) were considered, and isotopes were automatically 
excluded.
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Glycan annotation
The final peak list was submitted to glycan annotation 
using the PeakFinder tool (http://www.eurocarbdb.org/
ms-tools/), which was included in GlycoWorkbench ver 
2.1 build 146 (http://www.eurocarbdb.org/). The search 
parameters were a 5 ppm mass tolerance and a negative 
charge. The separation of the fragments measured into 
N-glycan-, O-glycan-, and glycosaminoglycan fragments 
was accomplished using the GlycoMod tool (http://web.
expasy.org/glycomod/) and a search of the current literature 
[2, 3]. In addition, METLIN (https://metlin.scripps.edu/) 
and Human Metabolome Database (http://www.hmdb.ca/) 
were used as supplementary database.
Glycan validation experiments
Glycan annotation was validated using tandem 
mass spectrometry (MS/MS) on extracts of TMA FFPE 
gastric cancer sections, which were first transferred into 
a 1.5 mL reaction tube (Eppendorf, Hamburg, Germany) 
using a scalpel tip (Aesculap AG, Tuttlingen, Germany) 
and then extracted in 70% MeOH (Sigma-Aldrich). 
Extraction solution with the additive of 9-aminoacridine 
matrix solution (1:1) was used for the measurements. For 
the validation experiments performed on the FT-ICR, the 
‘continuous accumulation of selected ions’ mode was used 
and collision-induced dissociation (CID) was activated in 
the collision cell. The resulting spectra were exported and 
compared with the CID spectra of hyaluronan (Sigma-
Aldrich) and chondroitin sulphate (Sigma-Aldrich) 
fragments that were generated by the addition of 0.1 M 
HCl (Sigma-Aldrich), which causes hydrolytic cleavage. 
Additionally fructose 6-phosphate (Sigma-Aldrich) was 
used for the validation of HexP.
Immunohistochemical staining and analysis
Expression levels of therapeutic targets such as 
HER2/neu, EGFR and MIB1 were determined using 
immunohistochemistry (IHC). The immunohistochemical 
stainings with anti-HER2/neu (A0785; 1:300, DAKO, 
Hamburg, Germany), anti-EGFR (pharmDx™-kit, 
DAKO) and anti-MIB1 (M7240; 1:100, DAKO) 
antibodies were performed on 3 μm consecutive sections 
using an automated slide processing system (Ventana 
DISCOVERY XT System, Ventana Medical Systems, 
Inc., Tucson, USA) in accordance with the manufacturer’s 
instructions. IHC staining and analysis were performed 
as previously described [37]. MIB1 score was defined as 
Score 0 (0 - 20% of all nuclei were positive), Score 1 (20 
– 50%), Score 2 (50 – 80 %) and Score 3 (80 - 100%).
Statistical analysis
In order to determine the prognostic power of each 
found glycan, the individual patient glycan fragment 
abundances were used to split the cohort into good and 
poor survivor groups by the application of intensity 
cut-offs, which were optimized to the clinical endpoint. 
Statistical differences in patient survival were determined 
using the Kaplan-Meier log-rank test. Multivariate survival 
analysis was performed using Cox proportional hazards 
regression models. All calculations were performed using 
R (‘survival’ package).
Further statistical testing for associations of the 
glycan abundances to the clinical data (Table 3), and 
therapeutic target expression levels was investigated 
using the Spearman’s rank correlation. Correlation-plots 
and calculations were generated and performed within R 
(‘corrplot‘ package).
Calculated p-values of the correlation analysis were 
adjusted using the “Benjamini-Hochberg” procedure. 
P-values equal or less than 0.05 were considered 
statistically significant.
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